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VEGFR1 is a receptor tyrosine kinase that has been implicated in cancer pathogenesis. It is upregulated in
angiogenic endothelial cells and expressed on human tumor cells as well. VEGFR1 positive hematopoietic
progenitor cells home to sites of distant metastases prior to the arrival of the tumor cells thus estab-
lishing a pre-metastatic niche. To discover high afﬁnity human antibodies selective for VEGFR1 molecular
imaging or for molecularly targeted therapy, a novel phage display scFv library was assembled and
characterized. The library was constructed from the humanized 4D5 framework that was mostly com-
prised tyrosine and serine residues in four complimentarity determining regions (CDRs). The library
produced diverse and functional antibodies against a panel of proteins, some of which are of biomedical
interest including, CD44, VEGFA, and VEGFR1. After panning, these antibodies had afﬁnity strong enough
for molecular imaging or targeted drug delivery without the need for afﬁnity maturation. One of the anti-
VEGFR1 scFvs recognized its cognate receptor and was selective for the VEGFR1.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The human vascular endothelial growth factor receptor-1
(VEGFR1 or Flt-1) contributes to the pathogenesis of both neo-
plastic and inﬂammatory diseases [1]. In human cancer, VEGFR1
mediated signaling is responsible for angiogenesis. In animal
models for example, inhibition of VEGFR1 signaling by peptides
reduces angiogenesis of xenografted human tumors [2]. VEGFR-1
mediated activation of nonmalignant supporting cells such as tu-
mor associated macrophages, are also likely important for cancer
pathogenesis. The expression of VEGFR1 on these macrophages is
associated with a more aggressive clinical phenotype of breast
cancer [3]. Finally, in response to chemokine activity within the
primary tumor, VEGFR1 positive hematopoietic progenitor cells
preferentially localize to pre-metastatic sites [4]. Because of the
involvement of VEGFR1 in cancer pathogenesis, our goal is to de-
velop high afﬁnity antibodies for molecular imaging or molecu-
larly targeted therapy of cancer. To supply these antibodies, we
assembled and characterized a phage displayed scFv library.
While most approaches in creating diversity through degen-
erate codons draw from all or most of the genetically encodedB.V. This is an open access article u
rds).
cript.amino acids, previous work with a phage displayed Fab library has
shown that restricting diversity to only two amino acids consisting
of tyrosine (Tyr) and serine (Ser) can yield high afﬁnity antibodies
in a few rounds of panning without the need for further afﬁnity
maturation which is a highly prized characteristic for a phage
displayed library [5,6]. Whereas Fab molecules are generally re-
garded as more stable than single chain variable fragment anti-
bodies (scFvs), the scFv format offers some distinct advantages.
Fab antibodies are heterodimers composed of a VH–CH1 and a
VL–CL domain while scFvs, comprised the VH and VL chains linked
by a ﬂexible peptide linker, are monomeric. As single molecules,
scFvs have a greater efﬁciency of functional display on ﬁlamentous
phage and they are amenable to fusion with other monomeric
proteins [7–9]. Additionally, like Fabs, scFvs have demonstrated
efﬁcacy in vivo, as tumor imaging agents, when labeled with near
infrared dyes or radioisotopes and as mediators of molecularly
targeted gene delivery [10]. Further, as monomers, scFvs are
readily converted to either minibodies or a diabodies for multi-
valent effects [11]. These bivalent formats offer superior properties
for molecular imaging in experimental animal models, without
concern for a loss of afﬁnity upon conversion and are attractive for
the development of high-afﬁnity ligands for cell surface receptors
[11].
Therefore, we have designed and constructed a scFv phage
display library for selection of high afﬁnity functional antibodies
for molecular targeting of VEGRF1. The library (BCscFv library) wasnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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residues in all of the CDRs of variable heavy chain (VH) and in the
CDR3 of variable light chain VL [12]. The library was built upon the
humanized and stable 4D5 framework [13]. After the new library
was characterized, and the diversity was determined, the func-
tionality of the library was tested by screening against a variety of
antigens which included hemoglobin, ubiquitin, VEGFA, CD44, as
well as our antigen of interest, VEGFR1.2. Materials and methods
Phusion high-ﬁdelity DNA polymerase, restriction en-
donucleases NcoI, DpnI and NotI, and T4 DNA ligase are purchased
from New England BioLabs. TG1 phage display competent cells
were purchased from Lucigen. Gel Extraction Kit, PCR Puriﬁcation
Kit, and plasmid Spin Miniprep Kit were purchased from Qiagen.
Protein Prestained Standards are purchased from BioRad.
2.1. Phagemid construction
The pIT2 vector was used as a parent vector for a phagemid
construction. Nucleotide sequences of scFvs of the humanized 4D5
antibody were spanned by restriction enzyme sites NcoI and NotI
and synthesized for cloning into pUC57 vector from GenScript. The
synthesized sequences were digested and puriﬁed using agarose
gel electrophoresis, and ligated into NcoI and NotI digested pha-
gemid pIT2 using T4 DNA ligase. After transformation, positives
were selected by colony PCR screening and further conﬁrmed by
DNA sequencing (Genewiz) using puriﬁed phagemids.
2.2. Site-directed mutation by PCR and TG1 electroporation
To introduce mutations, primers containing binary code of Tyr
and Ser were designed as previously described and synthesized
from Integrated DNA technology with 5′ phosphate modiﬁcation
(Table S1) [12]. Site-directed mutagenic PCRs were prepared using
Phusion polymerase (2 U/reaction), with a reaction system con-
taining 80 ng of template plasmid, 1phusion HF buffer, 7%
DMSO (v/v), 55 pmol of forward and backward primers, 10 pmol of
dNTPs, and H2O added to ﬁnal volume as 50 μL. PCR reactions
were performed using a BioRad T100 Thermal Cycler programmed
as follows: 2 min at 98 °C; 35 cycles of 40 s at 98 °C, 1 min at 68 °C,
3 min at 72 °C; 10 min at 72 °C; hold at 4 °C. PCR products were
incubated with 1 unit endonuclease DpnI overnight at 37 °C to
digest the template plasmid. The next day, DpnI was inactivated by
heating for 10 min at 80 °C. PCR products were resolved on a 1%
agarose gel. The target DNA fragment was excised and puriﬁed
with a Gel Puriﬁcation Kit. Self-ligation was accomplished with T4
ligase for 72 h at 16 °C. Ligation reactions were heat-inactivated for
15 min at 70 °C.
The ligated plasmids were puriﬁed from the ligation reactions
with a PCR Puriﬁcation Kit, and were electroporated into TG1
electrocompetent cells (Lucigen) as described in the manufacture’s
protocol. Brieﬂy, 1 μL of ligated plasmid was mixed with 25 μL of
ice-thawed TG1 and transferred into an ice-cooled 0.1 cm gap
cuvette (BioRad). Electroporation was carried out with a BioRad
Gene Pulser using the following conditions: 10 μF, 600 Ω, and
1800 V. Within 10 s of the pulse, 975 μL of warm kit-provided
recovery mediumwas added to resuspend the cells, and they were
transferred to a culture tube. After cells were recovered for 1 h at
37 °C, 10 μL of the cells were used for titration with serial dilu-
tions. The rest was cultured for phage library preparation.2.3. Screening the BCscFv library
BCscFv library was constructed (Fig. S1, Table S2) and char-
acterized (Fig. S2).
The antigens, ubiquitin (R&D Systems), hemoglobin (Sigma),
VEGFA (Sino Biological), VEGFR1 (R&D Systems), and CD44 (R&D
Systems), were incubated in 96-well Nunc Maxisorp plates
(Thermo Scientiﬁc) at 4 °C for 16–20 h for immobilization. For
stringent phage selections, the amount of antigen for im-
mobilization was gradually decreased: ﬁrst round: 5 mg/mL, sec-
ond round: 2.5 mg/mL, and third round: 1.25 μg/mL in PBS
(100 mL). After each well was rinsed with PBST (PBS containing
0.05% Tween-20), non-speciﬁc binding sites were blocked with
alternating proteins (300 μL) to prevent the emergence of phage
that bind the blocking protein for 2 h (ﬁrst round: 0.5% BSA in PBS,
second round: 0.5% ovalbumin in PBS, and third round: 0.5% casein
in PBS). The plate was rinsed with PBST, and phages in blocking
buffer (100 μL, 1013 CFU/mL) were added to the plates for afﬁnity
selection and incubated for 2 h at room temperature. The wells
were rinsed three times with PBST in the ﬁrst and second rounds
of screening and ten times in the third round of screening. The
remaining scFv-expressing phages were eluted by a treatment
with trypsin (100 μL/well, 1 mg/mL in PBS) for 10 min. The eluted
phage were collected and stored at 4 °C for titration or
ampliﬁcation.
2.4. Phage ELISA
96-well plates were coated with antigens or BSA overnight
(0.5 μg in 100 μL of PBS) and washed three times with PBST. The
non-speciﬁc binding was blocked with a blocking solution (5%
non-fat milk in PBS, 300 μL) for 2 h followed by washing (3 ,
PBST). Blank wells received only the blocking solution (n¼96). The
phages in 5% non-fat milk in PBS (100 μL, 1013 CFU/mL) were ad-
ded to the antigen- or BSA-immobilized wells and incubated for
1 h followed by rinsing with PBST (10 , 300 μL). Each well was
incubated with an HRP-anti-M13 antibody (1:5000, 100 μL; GE
Healthcare Life Sciences, 27-9421-01) for 1 h. The wells were
washed (8 , PBST), and HRP enzyme substrate solution (100 μL/
well; BioRad, 172-1064) was added into the wells. The enzymatic
reaction was stopped using H2SO4 (2 N, 100 μL), and the plate was
read at OD 450 nm (SynergyH4 Hybrid Reader, BioTek). Means of
the BSA-controls (n¼96) plus three times the standard deviation
(SD) are set as cut-off for positives [14].
2.5. Confocal microscopy of VEGFR1 expressing cell lines
The cell lines SK-BR3, U87 was seeded for 48 h and ﬁxed with
Methanol/Acetone (V:V¼1:1) for 10 min at 20 °C, following by
modiﬁed protocol descripted in supplemental data. Fluorescence
microscopic images were taken with a Zeiss Observer.Z1/Apotome
2 Microscope (Carl Zeiss) equipped with an EMCCD camera
(Evolve 512 Delta, Photometrics, Tuscon, AZ).3. Results
3.1. Characterization of the library with phage display against ﬁve
human antigens
To assess the functionality of the BCscFv phage library, bio-
panning was performed with ﬁve human antigens: hemoglobin,
VEGFA, ubiquitin, CD44 and VEGFR1. The antigen amounts were
decreased during panning to increase stringency. In some cases
the enrichment values decreased for the third round of panning
(hemoglobin and ubiquitin) (Table S3). To verify antigen mediated
Table 1






Hemoglobin 15/96 24/24 1.2109–9.3107
VEGFR-1 76/96 22/24 1.0109–1.9106
VEGF-A 14/96 24/24 1.6109–1.9105
Ubiquitin 40/96 24/24 3.7108–1.3106
CD44 96/96 24/24 1.0109–1.0105
a Numbers of positive clones/total clones.
b Numbers of unique clones/total clones.
c KD from a single concentration assuming a 1:1 binding model.
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further ampliﬁed and polyclonal phage ELISA was performed (Fig.
S1). Higher signals from target antigen-bound phages were ob-
served compared to the BSA or the blank controls, indicating a
successful enrichment for all of the antigens (results for VEGR1
and hemoglobin shown, Fig. S3). Individual phage colonies (96)
were then randomly picked and ampliﬁed for monoclonal phage
ELISA, and positive monoclonal phage clones were obtained (14.6–
100% positive) from the screened clones (Table 1). From these
clones, 24 were selected for sequencing (additional clones were
selected at random for hemoglobin and VEGFA) of the CDRs that
contained the binary code. The selection process yielded se-
quences that were highly unique for all the antibodies that were
selected (Tables 1 and S4). All 24 soluble scFvs for each antigen
were subjected to analysis by SPR at a single concentration. In each
group, there was a mixture of low and high afﬁnity antibodies
(Table 1).
Due to the interest of VEGFR1 as a marker for cancer patho-
genesis, clones obtained from panning against VEGFR1 were ex-
amined in detail. Unique sequences (22) were among the SPR-
tested antibodies (Table 1). Amino acid sequences of 4 mutated
CDR regions in 10 unique full-length clones had different lengths
of CDR-VH3, with 10–17 mutated binary amino acids and different
code patterns in all CDRs (Table S4). Clones (24) with robust ELISA
signals were selected for the production of soluble scFvs
(27 kDa) on a small-scale (8 mL of bacterial culture) for afﬁnity
determination by SPR. These scFvs (22/24, where one clone ap-
peared three times (B09/C01/C02), bound to the immobilized
VEGFR1 with equilibrium dissociation constants (KD) of 7.1109
to 3.8107 M. SPR analysis of clones (A03, A07, A08, B06, B09/
C01/C02, B11, C04, C06, E05, E06, F02, F06, and G08) demonstrated
speciﬁc binding to VEGFR1 (Table S4). The KD of 10 unique scFvs is
in the low-nanomolar range, 7.1–29.4 nM. The afﬁnity of scFv A07
was investigated at multiple concentrations to immobilized
VEGFR1 and VEGFR2 which shares high homology with VEGFR1
(Fig. 1). There was an approximate 5-fold decrease in afﬁnity as
determined by multi-concentration analysis compared to theFig. 1. Sensorgrams of anti-VEGFR1 scFv clone A07 to immobilized (A) VEGFR1 (KD¼40.afﬁnity determined from a single concentration (KD¼40.1 nM
from KD¼7.1 nM) and there was no observed binding to VEGFR2
(Fig. 1). This data indicates that the single concentration analysis is
a reasonable estimate of afﬁnity and that scFv A07 is not cross-
reactive to a protein that shares high homology with its antigen. In
addition to the 10 unique full-length scFv clones against VEGFR1,
we also discovered 12 clones that contained truncated sequences
(in correct frame with the pIII protein). The molecular weights of
the truncated scFv clones (16 kDa) were conﬁrmed by electro-
phoresis in SDS-PAGE gels (Fig. S4). The binding properties of the
truncated antibodies were measured by SPR: 3/12 clones (B06, C04
and C06) showed relatively high afﬁnity (KD¼22.1–375.0 nM),
whereas the rest of the clones (9/12) showed relatively weak af-
ﬁnities (KD4400 nM). Sequencing analysis of the three high bin-
ders from the truncated clones (B06, C04 and C06) demonstrated
that they contained only the heavy chain.
3.2. Immunoﬂuorescence microscopy of VEGFR1 expression in tissue
using anti-VEGFR1 scFv (A07)
Human breast carcinoma cells (SK-BR3) are known to express
VEGFR1 which plays key regulatory roles in tumor cell growth and
survival [15]. Utilizing confocal microscopy, Anti-VEGFR1 scFv
(A07) was tested with this cell line to determine whether it could
recognize cognate receptor. Incubation of the SK-BR3 with anti-
VEGFR1 scFv (A07) followed with anti-His tag mAb Alexa Fluor
488 conjugate showed intense pericellular staining (Fig. 2A) in
contrast to the staining of cell line U87 (Fig. 2A), a VEGFR1-ne-
gative control, with no detectable signal [16]. As a positive control,
a commercially available anti-VEGFR1 antibody conjugated with
Flour 488 was employed. As predicted, there was higher staining
in SK-BR3 cell line relative to the VEGFR1-negative (Fig. 2C) U87
cell line (Fig. 2D). Additionally, tumor xenografts from mice de-
veloped from SK-BR3 were used for preparing slides and im-
munohistochemistry (Fig. S5). The greatly reduced ﬂuorescence
from anti-VEGFR1 Mab DyLight 488 by co-treatment with 100-fold
molar excess anti-VEGFR1 scFv (A07) indicates that most of
VEGFR1 binding sites were blocked by anti-VEGFR1 scFv (A07)
(Fig. S5C).4. Discussion
The technology of phage display allows the assembly of a large
repertoire of antibodies, and through afﬁnity based selection, the
isolation of antibodies of high afﬁnity and speciﬁcity for the tar-
geted antigens or haptens [17]. A general and successful approach
has been to maximize the natural diversity of genetically encoded
amino acids in the hypervariable regions. Generally, greater di-
versity corresponds to the discovery of higher afﬁnity antibodies1 nM) and (B) VEGFR2 (no binding observed). Each experiment was repeated twice.
Fig. 2. Confocal microscopy images of VEGFR1 expressing human cell lines (SKBR3 and U87). The cells were incubated with anti-VEGFR1 mAb DyLight 488 (C and D). Cells
were incubated with anti-VEGFR1 scFv (clone A07, 30 mg/mL) followed by anti-His tag mAb Alexa Fluor 488 at room temperature (A and B). DAPI (a) was used for nucleus
counter staining in blue. Fluor 488 staining appears in red (b). Column (c) shows the merged picture of (a) and (b). (Scale bar¼10 mm).
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bodies, constructed from a simple binary code consisting of Tyr
and Ser in the hypervariable regions has also been successful [20].
When screened against a panel of diverse protein antigens, a Fab
library comprised mostly Tyr and Ser in the hypervariable regions
yielded antibodies with afﬁnities in the single-digit nanomolar
range with unique sequences [20]. Antibodies with such afﬁnities
could be used directly for a variety of purposes such as molecular
based therapies or afﬁnity matured for even higher afﬁnities. We
constructed a scFv library based on the binary code and demon-
strated that the library covered the theoretical diversity and pro-
duced high afﬁnity antibodies to a variety of proteins that rivaled
libraries with a high degree of utility and greater diversity [13,21].
After assessing the quality of the library through PCR colony
screening, immunoblotting, and DNA sequencing, we found that a
very high percentage of clones expressed the full scFv sequence
(Table S2 and Fig. S3A and S3B). These results compare favorably to
other synthetic libraries of high utility [13,21]. The diversity of the
library was reduced over the previously described Fab library;
however, we were still able to discover soluble and functional
antibodies for a number of antigens [20].
After conﬁrming that the construction of the library was sound,
it was tested to determine whether it could deliver a diverse set offunctional antibodies for a variety of antigens. Included in these
antigens are proteins of relevance in cancer and other diseases.
Human VEGFA is over expressed in most human tumors and
promotes angiogenesis of tumors. The receptor for VEGFA,
VEGFR1, is implicated in tumor progression and dissemination [1–
4,15]. CD44, a hyaluronic acid receptor, is upregulated in tumor
cells and has been identiﬁed as a cancer stem cell marker [22].
These proteins, together with other common proteins, were as-
sembled as a panel to test the BCscFv library. After three rounds of
panning, high afﬁnity antibodies, based on an apparent KD de-
termined at one concentration, were discovered for all tested an-
tigens, except for ubiquitin. Additionally, all or most of the se-
quences recovered were unique. The intended use of the library is
for the discovery of ligands to cell surface antigens for non-in-
vasive diagnostic imaging or molecular therapies in cancer and
other diseases [23]. To be effective for molecular imaging, the
minimum afﬁnities (KD) should be less than 100 nM. The best
tumor accumulations generally occur with scFvs of KDo10 nM
and kd at least on the order of 1103 s1 [24].
Immunoﬂuorescence microscopy of cell lines and frozen tumor
tissue conﬁrmed that the anti-VEFGR1 scFv (A07) discovered from
BCscFv library is fully functional (Figs. 2 and S5). To demonstrate
the selectivity of anti-VEFGR1 scFv (A07), commercially available
Fig. 3. Turbidity measurements of scFvs. Binary code scFvs (A03, A07, and A08)
were resistant to aggregation compared to the scFvs (J41-WT and J41-mutant)
containing normal complement of amino acids. Any pair differ signiﬁcantly
(Po0.01) from each other. Each measurement was repeated for 3 times. Error bars
represent standard deviation of the mean.
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of A07 on tumor tissue (SK-BR3 human breast cancer xenograft
tissue) and inhibited the binding of the anti-VEGFR1-Mab thus
demonstrating that A07 binds an epitope of VEGFR1 in tumor
tissue. Additionally, A07 neither binds immobilized VEGFR2 in an
SPR experiment nor U87 human glioma cells, which do not ex-
press VEGFR1 [16]. This data indicates that the A07 is highly se-
lective for VEGFR1 and is not likely to suffer from signiﬁcant off-
target binding.
To demonstrate function of the exemplar VEGFR1 scFvs beyond
afﬁnity, their propensity towards heat-induced aggregation was
examined. Recent ﬁndings have shown that antibodies with re-
sistance toward heat-induced aggregation results in higher yields
in bacterial expression systems relative to those antibodies which
aggregate readily [25]. The turbidity test is a measure of colloidal
stability rather than thermodynamic stability, where a colloid is a
non-native state consisting of aggregates formed from unfolded or
partially folded species [26]. Some proteins can be highly ther-
modynamically stable but possess low colloidal stability [25]. For
scFvs that will be formulated under conditions requiring high
colloidal stability, such as lyophilization, ﬁltrations, and high
concentrations for small animal injections, the turbidity assay is a
rapid and inexpensive method of assessing this important para-
meter of stability. As shown in Fig. 3, we compared the aggrega-
tion propensity of an scFv, J41, that was isolated from the Tom-
linson Iþ J library with those from the BCscFv library [8]. Included
in the comparison was a mutated version of J41 that incorporated
a DED triad at the C-terminal and N-terminal ends of VH CDR3 and
within VH CDR1, and a DD mutation within VL CDR2 (Table S1).
This mutant did display greater resistance toward aggregation
than the wild type (J41-WT), which is consistent with the ob-
served stability of scFvs with the Asp and Glu mutation at the
beginning or end of the CDR regions [25]. By comparison, the
exemplar scFvs, A03, A07, and A08, had a range of aggregation
propensities. A08 was not aggregation resistant while A03 and A07
were more aggregation resistant than the mutant (J41-mutant).
These results suggest that the Ser and Tyr residues that comprise
the VH CDRs and VL CDR2 can contribute to relatively stable scFv
antibodies that are resistant to aggregation and do not speciﬁcally
contribute to aggregation which is apparently governed by other
sequence determinants.
In conclusion, to supply high afﬁnity antibodies for molecular
targeting of VEGFR1, a new scFv phage library was constructed
with the humanized 4D5 framework that incorporated a pre-
dominate fraction of tyrosine and serine residues in the CDRs.
When the library was panned against a panel of proteins that in-
cluded proteins of biomedical interest, high afﬁnity antibodies
were isolated. Therefore, in three rounds of enrichment, the
BCscFv library has delivered a group of three scFvs for CD44,
VEGFR1, and VEGFA that are suitable in afﬁnity for further devel-
opment as molecularly targeted agents without the need forafﬁnity maturation. The screening results suggest that this new
library is highly functional. Further analysis of anti-VEGFR1-scFvs,
demonstrated that one of them, A07, recognized cognate receptor
on tumor tissue and demonstrated high afﬁnity in a multi-con-
centration analysis of binding kinetics by surface plasmon re-
sonance. This antibody, which is resistant to aggregation, is sui-
table for molecular imaging or targeted therapies of cancer where
VEGFR1 is upregulated as a result of the disease. To our best
knowledge, this is the ﬁrst functional anti-VEGFR1 scFv with CDRs
comprised of the binary code that would be suitable for for-
mulation as a bivalent construct such as a minibody or diabody for
molecular imaging or for fusion with other proteins for viral tar-
geting [27,28].Acknowledgments
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